Will Marrone Bio Innovations, Inc. (MBII) Short Squeeze Soon? The Stock Formed a Multiple Bottom Pattern

December 7, 2017 - By Louis Casey

Investors sentiment decreased to 0.86 in Q2 2017. Its down 0.14, from 1 in 2017Q1. It turned negative, as 3 investors sold Marrone Bio Innovations, Inc. shares while 4 reduced holdings. 1 funds opened positions while 5 raised stakes. 11.88 million shares or 32.33% more from 8.98 million shares in 2017Q1 were reported.
Bridgeway Mgmt stated it has 0% of its portfolio in Marrone Bio Innovations, Inc. (NASDAQ:MBII). Northern Trust Corp owns 24,738 shares for 0% of their portfolio. 520 are owned by Morgan Stanley. 2.70 million are held by Primecap Mgmt Com Ca. Waddell & Reed Fincl stated it has 4.71 million shares or 0.01% of all its holdings. Hanson Mcclain holds 10,000 shares or 0% of its portfolio. Spark Inv Ltd Liability invested in 0% or 60,800 shares. Creative Planning reported 0% of its portfolio in Marrone Bio Innovations, Inc. (NASDAQ:MBII). Ardsley Advisory Ptnrs owns 3.68 million shares or 0.81% of their US portfolio. Vanguard Gp Inc has 0% invested in Marrone Bio Innovations, Inc. (NASDAQ:MBII) for 314,908 shares. Raymond James Serv invested in 16,961 shares. Savant Cap Lc invested in 11,067 shares or 0% of the stock. Geode Cap Ltd invested 0% in Marrone Bio Innovations, Inc. (NASDAQ:MBII). Blackrock owns 79,000 shares or 0% of their US portfolio. Ogorek Anthony Joseph New York Adv owns 300 shares.

The stock of Marrone Bio Innovations, Inc. (MBII) shows a multiple bottoms pattern with $0.92 target or 5.00 % below today’s $0.96 share price. The 9 months chart pattern indicates high risk for the $30.25 million company. It was reported on Dec, 7 by Finviz.com. If the $0.92 price target is reached, the company will be worth $1.51M less.
Multiple bottoms are very good trading chart patterns. These patterns have a low break even failure rate and decent average rise in a bull market, giving them a solid performance rank. Back-tests of such patterns show that the break even failure rate is 4%, the average rise: 37%, the throwback rate: 64% and the percentage of stocks meeting their price targets: 64%.

The stock decreased 1.54% or $0.0151 during the last trading session, reaching $0.9649. About 255,611 shares traded or 102.47% up from the average. Marrone Bio Innovations, Inc. (NASDAQ:MBII) has risen 94.03% since December 7, 2016 and is uptrending. It has outperformed by 77.33% the S&P500.

Marrone Bio Innovations, Inc. (NASDAQ:MBII) Ratings Coverage

Among 3 analysts covering Marrone Bio Innovations (NASDAQ:MBII), 2 have Buy rating, 0 Sell and 1 Hold. Therefore 67% are positive. Marrone Bio Innovations has $3.50 highest and $100 lowest target. $3’s average target is 210.91% above currents $0.9649 stock price. Marrone Bio Innovations had 6 analyst reports since August 11, 2015 according to SRatingsIntel. The firm earned “Hold” rating on Monday, August 14 by Piper Jaffray. Rodman & Renshaw initiated the stock with “Buy” rating in Wednesday, March 16 report. The firm has “Hold” rating by Piper Jaffray given on Friday, July 21. The firm has “Buy” rating by Zacks given on Tuesday, August 11. The rating was maintained by Piper Jaffray on Friday, September 15 with “Hold”. The firm earned “Buy” rating on Tuesday, August 15 by H.C. Wainwright.

More notable recent Marrone Bio Innovations, Inc. (NASDAQ:MBII) news were published by: Seekingalpha.com which released: “Marrone Bio Is Approaching Bankruptcy And Will Have A Brutal Equity Offering …” on December 05, 2017, also Globenewswire.com with their article: “Marrone Bio Innovations Adds Three Commercial Managers for Southeast, West …” published on December 04, 2017, Globenewswire.com published: “Marrone Bio Innovations to Present at The MicroCap Conference in New York on …” on September 28, 2017. More interesting news about Marrone Bio Innovations, Inc. (NASDAQ:MBII) were released by: Globenewswire.com and their article: “Marrone Bio Innovations, Inc. Reports Second Quarter 2017 Financial Results” published on August 14, 2017 as well as Seekingalpha.com‘s news article titled: “Marrone Bio Innovations’ (MBII) CEO Pamela Marrone on Q3 2017 Results …” with publication date: November 14, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.